100050
1400W dihydrochloride
≥95% (HPLC), nitric oxide synthase inhibitor, solid
別名:
1400W, N-(3-Aminomethyl)benzylacetamidine, 2HCl
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C10H15N3 · 2HCl
CAS番号:
分子量:
250.17
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥95% (HPLC)
Form:
solid
Storage condition:
OK to freeze, desiccated (hygroscopic)
製品名
1400W, A selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM).
Quality Segment
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic)
color
white
solubility
water: 1 mg/mL, methanol: 5 mg/mL
shipped in
ambient
storage temp.
−20°C
InChI
1S/C10H16N3/c1-8(12)13-7-10-4-2-3-9(5-10)6-11/h2-5,13H,6-7,11-12H2,1H3/q+1/p+1
InChI key
FFSSUWWXUDLVQZ-UHFFFAOYSA-O
General description
A selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM). Suitable for use in both in vitro and in vivo systems. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
A selective, irreversible, slow, tight binding inhibitor of inducible nitric oxide synthase (iNOS, Kd = 7 nM) both in vitro and in vivo. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
Biochem/physiol Actions
Cell permeable: yes
Kd = 7 nM against inducible nitric oxide synthase (iNOS)
Primary Target
iNOS
iNOS
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
Other Notes
Parmentier, S., et al. 1999. Br. J. Pharmacol.127, 546.
Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Still not finding the right product?
Explore all of our products under 1400W
保管分類
11 - Combustible Solids
一体何が起きているの？
WGK 3
引火点 (F)
Not applicable
引火点（°C）
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
100050-5MG:
jan